AIDS‐associated Cryptococcus neoformans and Penicillium marneffei coinfection: a therapeutic dilemma in resource‐limited settings.
暂无分享,去创建一个
[1] Philimon N. Gona,et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] S. Jaffar,et al. Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] A. Zolopa,et al. Early Antiretroviral Therapy Reduces AIDS Progression/Death in Individuals with Acute Opportunistic Infections: A Multicenter Randomized Strategy Trial , 2009, PloS one.
[4] E. Lanino,et al. Voriconazole for Cryptococcal Meningitis in Children with Leukemia or Receiving Allogeneic Hemopoietic Stem Cell Transplant , 2009, Journal of chemotherapy.
[5] S. Jaffar,et al. Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] Daryl S Schiller,et al. Posaconazole: an extended-spectrum triazole antifungal agent. , 2007, Clinical therapeutics.
[7] H. Schlamm,et al. Voriconazole as therapy for systemic Penicillium marneffei infections in AIDS patients. , 2007, The American journal of tropical medicine and hygiene.
[8] P. Pitisuttithum,et al. Activity of posaconazole in the treatment of central nervous system fungal infections. , 2005, The Journal of antimicrobial chemotherapy.
[9] O. Kirk,et al. Safe Interruption of Maintenance Therapy against Previous Infection with Four Common HIV-Associated Opportunistic Pathogens during Potent Antiretroviral Therapy , 2002, Annals of Internal Medicine.
[10] Alimuddin Zumla,et al. Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions , 2001, Postgraduate medical journal.
[11] K. Nelson,et al. A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human immunodeficiency virus. , 1998, The New England journal of medicine.
[12] K. Nelson,et al. Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in human immunodeficiency virus-infected patients. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] M. Saag,et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. , 1997, The New England journal of medicine.
[14] S. Pauluzzi,et al. High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] K. Nelson,et al. Disseminated Penicillium marneffei infection in Southeast Asia , 1994, The Lancet.
[16] K. Nelson,et al. Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens , 1993, Antimicrobial Agents and Chemotherapy.
[17] J. Scavone,et al. Pharmacokinetics and bioavailability of fluconazole in patients with AIDS , 1993, Antimicrobial Agents and Chemotherapy.
[18] R. Negroni,et al. Itraconazole: pharmacokinetics and indications. , 1993, Archives of medical research.